June 11, 2024AgingOpen Access

Attenuating bone loss in osteoporosis: the potential of corylin (CL) as a therapeutic agent

View Full Paper

Ask AI

Bookmark

Authors

SZSong ZhouYangzhou Polytechnic Institute JHJunming HuangZhejiang International Studies University KCKun ChenCentral South University

Discussion

Member takes

Implication

Preclinical study demonstrates attenuation of ovariectomy-induced bone loss by corylin in animal models, highlighting its therapeutic potential for osteoporosis.

Key Points

Corylin suppresses osteoclast differentiation and reduces bone resorption capacity by downregulating essential transcription factors NFATc1 and c-fos in vitro.
In vivo evaluation reveals that corylin attenuates ovariectomy-induced bone loss, while cellular assays confirm reduced pre-osteoclast migration and fusion.
These findings suggest corylin offers a novel drug strategy for managing osteoporosis; ovariectomized mouse model; further preclinical evaluation is warranted.

Cite This Study

Zhou et al. (2024) studied this question.

synapsesocial.com/papers/68e65438b6db6435875e393f https://doi.org/10.18632/aging.205885

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates attenuation of ovariectomy-induced bone loss by corylin in animal models, highlighting its therapeutic potential for osteoporosis.

Attenuating bone loss in osteoporosis: the potential of corylin (CL) as a therapeutic agent

Discussion

Member takes

Implication

Key Points

Cite This Study

Attenuating bone loss in osteoporosis: the potential of corylin (CL) as a therapeutic agent

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider